0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Anal Cancer Epidemiology Forecast to 2028
Published Date: February 2019
|
Report Code: DELV-Epid-422
Home | Market Reports | Health | Health Conditions
Anal Cancer Epidemiology Forecast to 2028

Anal Cancer Epidemiology Forecast to 2028

Code: DELV-Epid-422
Report
February 2019
Pages:50
Delveinsight
Description
Table of Content
Tables & Figures

DelveInsight's "Anal Cancer  - Epidemiology Forecast, 2028” report provides a comprehensive analysis of the Anal Cancer  epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

 Study Period: 2016-2028

Anal Cancer  Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Anal Cancer  in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Anal Cancer  outlook. It also includes the explanation of changing trends of epidemiology outlining the Anal Cancer  scenario.

Anal Cancer  Epidemiology Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Anal Cancer  thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope
• The report covers detailed overview of Anal Cancer  explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Anal Cancer  Report assesses the disease risk and burden and highlights the unmet needs
• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths
• 10 Year Forecast
• 7MM Coverage
• Total Cases in Anal Cancer 

Key assessments
• Patient Segmentation in Anal Cancer 
• Anal Cancer  Risk & Burden
• Factors driving growth in a specific Anal Cancer  patient population

1.Report Introduction
2. Anal Cancer  Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Anal Cancer  in 2016
2.2. Patient Share Distribution of Anal Cancer  in 2028
3. Disease Background and Overview: Anal Cancer 
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Anal Cancer  in 7MM
4.3. Total Prevalent/ Incident Patient Population of Anal Cancer  in 7MM – By Countries
5. Epidemiology of Anal Cancer  by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Anal Cancer 
5.1.3. Sub-Type Specific cases of the Anal Cancer  *
5.1.4. Sex- Specific Cases of the Anal Cancer *
5.1.5. Diagnosed Cases of the Anal Cancer 
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Anal Cancer 
5.4.3. Sub-Type Specific cases of the Anal Cancer *
5.4.4. Sex- Specific Cases of the Anal Cancer *
5.4.5. Diagnosed Cases of the Anal Cancer 
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Anal Cancer 
5.5.3. Sub-Type Specific cases of the Anal Cancer *
5.5.4. Sex- Specific Cases of the Anal Cancer *
5.5.5. Diagnosed Cases of the Anal Cancer 
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Anal Cancer 
5.6.3. Sub-Type Specific cases of the Anal Cancer *
5.6.4. Sex- Specific Cases of the Anal Cancer *
5.6.5. Diagnosed Cases of the Anal Cancer 
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Anal Cancer 
5.7.3. Sub-Type Specific cases of the Anal Cancer *
5.7.4. Sex- Specific Cases of the Anal Cancer *
5.7.5. Diagnosed Cases of the Anal Cancer 
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Anal Cancer 
5.8.3. Sub-Type Specific cases of the Anal Cancer *
5.8.4. Sex- Specific Cases of the Anal Cancer *
5.8.5. Diagnosed Cases of the Anal Cancer 
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Anal Cancer 
5.9.3. Sub-Type Specific cases of the Anal Cancer *
5.9.4. Sex- Specific Cases of the Anal Cancer *
5.9.5. Diagnosed Cases of the Anal Cancer 
6. Unmet Needs of the Anal Cancer 
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific

 

Table 1: Total Prevalent/Incident Cases of the Anal Cancer  in 7MM
Table 2: Total Prevalent/Incident Cases of the Anal Cancer  in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Anal Cancer  in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Anal Cancer  in United States (2016-2028)*
Table 5: Sex- Specific Cases of the Anal Cancer  in United States (2016-2028)*
Table 6: Diagnosed Cases of the Anal Cancer  in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Anal Cancer  in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Anal Cancer  in Germany (2016-2028) *
Table 9: Sex- Specific Cases of the Anal Cancer  in Germany (2016-2028) *
Table 10: Diagnosed Cases of the Anal Cancer  in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Anal Cancer  in France (2016-2028)
Table 12: Sub-Type Specific cases of the Anal Cancer  in France (2016-2028) *
Table 13: Sex- Specific Cases of the Anal Cancer  in France (2016-2028) *
Table 14: Diagnosed Cases of the Anal Cancer  in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Anal Cancer  in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Anal Cancer  in Italy (2016-2028) *
Table 17: Sex- Specific Cases of the Anal Cancer  in Italy (2016-2028) *
Table 18: Diagnosed Cases of the Anal Cancer  in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Anal Cancer  in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Anal Cancer  in Spain (2016-2028) *
Table 21: Sex- Specific Cases of the Anal Cancer  in Spain (2016-2028) *
Table 22: Diagnosed Cases of the Anal Cancer  in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Anal Cancer  in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Anal Cancer  in UK (2016-2028) *
Table 25: Sex- Specific Cases of the Anal Cancer  in UK (2016-2028) *
Table 26: Diagnosed Cases of the Anal Cancer  in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Anal Cancer  in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Anal Cancer  in Japan (2016-2028) *
Table 29: Sex- Specific Cases of the Anal Cancer  in Japan (2016-2028) *
Table 30: Diagnosed Cases of the Anal Cancer  in Japan (2016-2028)

Figure 1: Total Prevalent/Incident Cases of the Anal Cancer  in 7MM
Figure 2: Total Prevalent/Incident Cases of the Anal Cancer  in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Anal Cancer  in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Anal Cancer  in United States (2016-2028)*
Figure 5: Sex- Specific Cases of the Anal Cancer  in United States (2016-2028)*
Figure 6: Diagnosed Cases of the Anal Cancer  in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Anal Cancer  in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Anal Cancer  in Germany (2016-2028) *
Figure 9: Sex- Specific Cases of the Anal Cancer  in Germany (2016-2028) *
Figure 10: Diagnosed Cases of the Anal Cancer  in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Anal Cancer  in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Anal Cancer  in France (2016-2028) *
Figure 13: Sex- Specific Cases of the Anal Cancer  in France (2016-2028) *
Figure 14: Diagnosed Cases of the Anal Cancer  in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Anal Cancer  in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Anal Cancer  in Italy (2016-2028) *
Figure 17: Sex- Specific Cases of the Anal Cancer  in Italy (2016-2028) *
Figure 18: Diagnosed Cases of the Anal Cancer  in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Anal Cancer  in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Anal Cancer  in Spain (2016-2028) *
Figure 21: Sex- Specific Cases of the Anal Cancer  in Spain (2016-2028) *
Figure 22: Diagnosed Cases of the Anal Cancer  in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Anal Cancer  in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Anal Cancer  in UK (2016-2028) *
Figure 25: Sex- Specific Cases of the Anal Cancer  in UK (2016-2028) *
Figure 26: Diagnosed Cases of the Anal Cancer  in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Anal Cancer  in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Anal Cancer  in Japan (2016-2028) *
Figure 29: Sex- Specific Cases of the Anal Cancer  in Japan (2016-2028) *
Figure 30: Diagnosed Cases of the Anal Cancer  in Japan (2016-2028)

SELECT A FORMAT
Added to Cart
Electronic (PDF)

$3250

This license allows only one user to access the PDF.
Electronic (PDF)

$6500

This license allows all the users of an enterprise residing in one location to access the PDF
Electronic (PDF)

$9750

This license allows all the employees of an enterprise to access the PDF.
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
SIS Group of Schools
SIMILAR REPORTS
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Clotting Factors Ⅷ Market Insights, Forecast to 2030

120 Pages
Type: Report
Code: QYRE-Auto-21S8513
Thu Dec 12 00:00:00 UTC 2024

Add to Cart

Rare Genetic Disease Diagnosis Solution - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages
Type: Report
Code: QYRE-Auto-17L15214
Thu Dec 12 00:00:00 UTC 2024

Add to Cart

Endoscopes for Otology - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages
Type: Report
Code: QYRE-Auto-19V14797
Thu Dec 12 00:00:00 UTC 2024

Add to Cart

Immunotherapy Drugs for Neuroblastoma - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages
Type: Report
Code: QYRE-Auto-39R14639
Thu Dec 12 00:00:00 UTC 2024

Add to Cart